Safety review
A review of harms, in which the absence of an event in a trial of conventional size is treated as uninformative rather than as reassurance.
Reviews
-
Do incretin-based therapies increase the incidence of acute pancreatitis?
Moderate22 Mar 2026 -
What is the incidence of gastrointestinal adverse events and of discontinuation for adverse events with incretin receptor agonists compared with placebo?
High12 Oct 2025 -
What is the evidence that glucagon-like peptide-1 receptor agonism increases the risk of medullary thyroid carcinoma in humans?
Low23 Aug 2024 -
Does treatment with a glucagon-like peptide-1 receptor agonist increase residual gastric content at the time of elective procedural sedation?
Low13 Feb 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High26 Apr 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High08 May 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Dulaglutide compared with its comparator?
High21 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High18 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High09 Oct 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High31 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its comparator?
Moderate10 Mar 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with semaglutide) compared with its comparator?
Moderate13 Jan 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Lixisenatide compared with its comparator?
High31 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its comparator?
Moderate05 May 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Survodutide compared with its comparator?
Moderate15 Jul 2025 -
Thymosin alpha-1 in immune modulation and adjunctive immunotherapy: tolerability and discontinuation
In the population defined for immune modulation and adjunctive immunotherapy, what is the incidence of adverse events leading to discontinuation with Thymosin alpha-1 compared with its comparator?
Moderate30 Mar 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High07 Jan 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High11 Mar 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its comparator?
Moderate18 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Mazdutide compared with its comparator?
Moderate02 Jun 2026
page 1 of 3